U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071688) titled 'Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy' on July 08.
Brief Summary: Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significant...